Table 1.
Clinical demographic characteristics of patients with and without febrile neutropenia in the training dataset.
| Parameters | FN group (n = 366) | non-FN group (n = 477) | p value |
|---|---|---|---|
| Age (years), means ± SD | 0.004 | ||
| ≤ 50 | 157 (42.9) | 276 (57.9) | < 0.001 |
| > 50 | 209 (57.1) | 201 (42.1) | |
| Body surface area (m2), means ± SD | 1.58 ± 0.14 | 1.57 ± 0.13 | 0.498 |
| Hypertension, n (%) | 112 (30.6) | 113 (23.7) | 0.028 |
| Diabetes mellitus, n (%) | 42 (11.5) | 44 (9.2) | 0.303 |
| Tuberculosis, n (%) | 9 (2.5) | 14 (2.9) | 0.832 |
| Breast-conserving surgery, n (%) | 201 (55.1) | 345 (72.3) | < 0.001 |
| Tumor size (cm), mean ± SD | 2.7 ± 2.0 | 2.3 ± 1.4 | 0.002 |
| Positive lymph node, means ± SD | 2.6 ± 5.2 | 1.2 ± 3.4 | < 0.001 |
| ER, n (%) | 268 (74.0) | 312 (66.0) | 0.012 |
| PR, n (%) | 225 (62.2) | 280 (59.2) | 0.392 |
| Her-2, n (%) | 108 (29.5) | 133 (27.9) | 0.645 |
| CA 15–3, means ± SD | 56.3 ± 202.0 | 24.0 ± 136.5 | 0.009 |
| TNM staging, n (%) | < 0.001 | ||
| I/II | 248 (67.8) | 410 (86.0) | |
| III/IV | 118 (32.2) | 67 (14.0) | |
| Taxane-based regimen, n (%) | 245 (66.9) | 184 (38.6) | < 0.001 |
| CBC (before chemotherapy), means ± SD | |||
| Hemoglobin (g/dL) | 12.9 ± 1.2 | 13.0 ± 1.4 | 0.426 |
| Platelet (× 103/µL) | 262 ± 63 | 269 ± 65 | 0.168 |
| Neutrophil (× 103/µL) | 3.725 ± 1.550 | 3.815 ± 1.420 | 0.383 |
| Lymphocyte (× 103/µL) | 1.905 ± 0.603 | 1.971 ± 0.621 | 0.119 |
| CBC (5 days after chemotherapy), means ± SD | |||
| Hemoglobin (g/dL) | 10.9 ± 1.7 | 11.5 ± 1.1 | < 0.001 |
| Platelet (× 103/µL) | 221 ± 82 | 226 ± 62 | 0.378 |
| Neutrophil (× 103/µL) | 3.329 ± 2.278 | 3.067 ± 1.343 | 0.052 |
| Lymphocyte (× 103/µL) | 0.867 ± 0.374 | 1.561 ± 0.593 | < 0.001 |
| SERM, n (%) | 139 (38.0) | 221 (46.3) | 0.017 |
| LHRH, n (%) | 112 (30.6) | 190 (39.8) | 0.006 |
| Aromatase inhibitor, n (%) | 148 (40.4) | 121 (25.4) | < 0.001 |
| Radiation treatment, n (%) | 292 (79.8) | 401 (84.1) | 0.122 |
| Herceptin, n (%) | 101 (27.6) | 130 (27.3) | 0.938 |
FN febrile neutropenia, SD standard deviation, BSA body surface area, ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, CA cancer antigen, CBC complete blood count, SERM selective estrogen receptor modulator, LHRH luteinizing hormone-releasing hormone, F/U follow-up.